- Home
- AVK vs TSHA Comparison
AVK vs TSHA Comparison
Compare AVK & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVK
- TSHA
- Stock Information
- Founded
- AVK 2003
- TSHA 2019
- Country
- AVK United States
- TSHA United States
- Employees
- AVK N/A
- TSHA N/A
- Industry
- AVK Trusts Except Educational Religious and Charitable
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- AVK Finance
- TSHA Health Care
- Exchange
- AVK Nasdaq
- TSHA Nasdaq
- Market Cap
- AVK 411.0M
- TSHA 356.7M
- IPO Year
- AVK N/A
- TSHA 2020
- Fundamental
- Price
- AVK $11.49
- TSHA $1.26
- Analyst Decision
- AVK
- TSHA Strong Buy
- Analyst Count
- AVK 0
- TSHA 8
- Target Price
- AVK N/A
- TSHA $6.63
- AVG Volume (30 Days)
- AVK 112.9K
- TSHA 2.4M
- Earning Date
- AVK 01-01-0001
- TSHA 05-13-2025
- Dividend Yield
- AVK 11.85%
- TSHA N/A
- EPS Growth
- AVK N/A
- TSHA N/A
- EPS
- AVK N/A
- TSHA N/A
- Revenue
- AVK N/A
- TSHA $8,333,000.00
- Revenue This Year
- AVK N/A
- TSHA N/A
- Revenue Next Year
- AVK N/A
- TSHA N/A
- P/E Ratio
- AVK N/A
- TSHA N/A
- Revenue Growth
- AVK N/A
- TSHA N/A
- 52 Week Low
- AVK $9.24
- TSHA $1.17
- 52 Week High
- AVK $12.16
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- AVK 37.10
- TSHA 32.22
- Support Level
- AVK $11.38
- TSHA $1.17
- Resistance Level
- AVK $11.89
- TSHA $1.87
- Average True Range (ATR)
- AVK 0.14
- TSHA 0.17
- MACD
- AVK 0.01
- TSHA -0.04
- Stochastic Oscillator
- AVK 21.57
- TSHA 12.18
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.